BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

XBiotech USA, Inc. Announces Addition to its Board of Directors


8/30/2013 6:24:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AUSTIN, Texas, Aug. 29, 2013 /PRNewswire/ -- XBiotech announced today that Dr. Fabrizio Bonanni has joined the Company as a member of the Board of Directors. Dr. Bonanni joins XBiotech after stepping down from Amgen this year where he ended his tenure as that Company's most senior officer in charge of operations. At Amgen, Dr. Bonanni held the position of Executive Vice President of Operations from 2007-2012, and between 1999-2007 held Senior Vice President positions in charge of manufacturing, quality and regulatory compliance. Prior to Amgen, Dr. Bonanni held the position of Corporate Vice President of Regulatory and Clinical Affairs at Baxter International.

XBiotech claims to have established manufacturing technologies that realize a dramatic reduction in capital requirements, shorter lead times, simpler regulatory compliance and unprecedented production flexibility compared to the complex manufacturing systems used by industry today. The Company plans to use this technology to produce its new True Human antibody therapeutics, and also to enable a highly competitive biosimilar business.

Dr. Bonanni stated, "I admire XBiotech's commitment to bring novel therapies to seriously ill people and do so with a new approach to biotechnology, which has the promise of high quality, fast response times, and better affordability. I am excited at the opportunity to contribute to XBiotech's success."

John Simard, the Company's Chairman & CEO commented, "I am delighted to have Fabrizio join XBiotech's Board of Directors. For years Fabrizio delivered on the responsibility to maintain drug supply and navigate the complex regulatory environment for the world's preeminent biopharmaceutical company. I believe his experience and knowledge will serve as a great asset to our innovative programs. For Fabrizio to give his confidence and share in our vision is indeed gratifying."

ABOUT XBIOTECH

XBiotech is leading the commercialization of biological therapiesincluding the discovery and development of True Human antibodies. The Company's lead product candidatein Phase III clinical studiesis a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and reduce lead times for biological drugs, ushering in a new era for cost and development efficiency in the biopharmaceutical industry.

Contact:
Investors:
Ashley Otero
XBiotech
info@xbiotech.com
512.386.2930

SOURCE XBiotech



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES